Literature DB >> 8218537

Effect of recombinant human erythropoietin after allogenic bone marrow transplantation.

H Link1, T Brune, G Hübner, H Diedrich, M Freund, M Stoll, D Peest, W Ebell, C Bettoni, W Oster.   

Abstract

The hematologic effects of recombinant human erythropoietin after allogeneic bone marrow transplantation (BMT) were studied. Nineteen patients received 150 U/kg/day of C127 mouse-cell-derived recombinant human erythropoietin (rHu EPO) as a daily continuous intravenous infusion until hematocrit exceeded 35%. These data were compared with a treatment-matched historical control group of 43 patients. RHu EPO-treated patients recovered erythropoiesis more rapidly and became independent from erythrocyte transfusions after a median of 17 days, which was 7 days earlier than the control patients.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8218537     DOI： 10.1007/bf01695863

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


  27 in total

1.  Serum erythropoietin levels in patients undergoing autologous bone marrow transplantation.

Authors:  A Bosi; A M Vannucchi; A Grossi; S Guidi; L Vannucchi; R Saccardi; P A Bernabei; G Longo; D Rafanelli; P Rossi-Ferrini
Journal:  Bone Marrow Transplant       Date:  1991-06       Impact factor: 5.483

2.  The mechanism of expansion of late erythroid progenitors during erythroid regeneration: target cells and effects of erythropoietin and interleukin-3.

Authors:  T Umemura; T Papayannopoulou; G Stamatoyannopoulos
Journal:  Blood       Date:  1989-05-15       Impact factor: 22.113

3.  Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy.

Authors:  L T Goodnough; S Rudnick; T H Price; S K Ballas; M L Collins; J P Crowley; M Kosmin; M S Kruskall; B A Lenes; J E Menitove
Journal:  N Engl J Med       Date:  1989-10-26       Impact factor: 91.245

4.  Committed erythroid progenitors and erythropoietin levels in anemic children with lymphomas and tumors.

Authors:  M Kalmanti; T Kalmantis
Journal:  Pediatr Hematol Oncol       Date:  1989       Impact factor: 1.969

5.  Erythropoietin treatment of anemia associated with multiple myeloma.

Authors:  H Ludwig; E Fritz; H Kotzmann; P Höcker; H Gisslinger; U Barnas
Journal:  N Engl J Med       Date:  1990-06-14       Impact factor: 91.245

6.  Impaired erythropoietin production in mice treated with cyclosporin A.

Authors:  A M Vannucchi; A Grossi; A Bosi; D Rafanelli; S Guidi; R Saccardi; R Alterini; P R Ferrini
Journal:  Blood       Date:  1991-09-15       Impact factor: 22.113

7.  Haemopoietic reconstitution after allogeneic bone marrow transplantation in man: recovery of haemopoietic progenitors (CFU-Mix, BFU-E and CFU-GM).

Authors:  D D Ma; D E Varga; J C Biggs
Journal:  Br J Haematol       Date:  1987-01       Impact factor: 6.998

8.  Effective therapy of human immunodeficiency virus-associated anemia with recombinant human erythropoietin despite high endogenous erythropoietin.

Authors:  N A DaCosta; M B Hultin
Journal:  Am J Hematol       Date:  1991-01       Impact factor: 10.047

9.  Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cells.

Authors:  M J Koury; M C Bondurant
Journal:  J Cell Physiol       Date:  1988-10       Impact factor: 6.384

10.  Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: results of a prospective controlled randomized trial.

Authors:  J L Steegmann; J López; M J Otero; M L Lamana; R de la Cámara; M Berberana; A Díaz; J M Fernández-Rañada
Journal:  Bone Marrow Transplant       Date:  1992-12       Impact factor: 5.483
View more
  2 in total

Review 1.  Clinical use of rHuEPO in bone marrow transplantation.

Authors:  S Klaesson
Journal:  Med Oncol       Date:  1999-04       Impact factor: 3.064

2.  Recommendations on RBC Transfusion Support in Children With Hematologic and Oncologic Diagnoses From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative.

Authors:  Marie E Steiner; Nicole D Zantek; Simon J Stanworth; Robert I Parker; Stacey L Valentine; Leslie E Lehmann; Cassandra D Josephson; Scot T Bateman; Naomi L C Luban
Journal:  Pediatr Crit Care Med       Date:  2018-09       Impact factor: 3.624
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.